Security Snapshot

Cytosorbents Corp - Common Stock (CTSO) Institutional Ownership

CUSIP: 23283X206

13F Institutional Holders and Ownership History from Q4 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

51

Shares (Excl. Options)

16,863,149

Price

$0.64

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
CTSO on Nasdaq
Shares outstanding
63,013,241
Price per share
$0.57
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,863,149
Total reported value
$10,779,444
% of total 13F portfolios
0%
Share change
+515,340
Value change
+$313,470
Number of holders
51
Price from insider filings
$0.57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CTSO - Cytosorbents Corp - Common Stock is tracked under CUSIP 23283X206.
  • 51 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 51 to 5 between Q4 2025 and Q1 2026.
  • Reported value moved from $10,779,444 to $1,035,593.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 51 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 23283X206?
CUSIP 23283X206 identifies CTSO - Cytosorbents Corp - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Cytosorbents Corp - Common Stock (CTSO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AVENIR CORP 8.3% +43% $3,817,972 +$1,559,392 5,230,099 +69% AVENIR CORP 31 Dec 2025
SATTERFIELD THOMAS A JR 6.6% $4,638,686 3,998,867 Thomas A. Satterfield, Jr. 13 Jan 2025
Avenue Venture Opportunities Fund, L.P. 5.7% $4,356,117 3,755,273 Avenue Capital Management II, L.P. 26 Jun 2024
Skylands Capital, LLC 4.8% -6% $3,483,134 +$256,453 3,002,702 +7.9% Skylands Capital, LLC 31 Mar 2025
VANGUARD GROUP INC 3.1% -57% $2,261,479 -$2,261,479 1,949,551 -50% The Vanguard Group 31 Mar 2025

As of 31 Dec 2025, 51 institutional investors reported holding 16,863,149 shares of Cytosorbents Corp - Common Stock (CTSO). This represents 27% of the company’s total 63,013,241 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cytosorbents Corp - Common Stock (CTSO) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
AVENIR CORP 8.3% 5,230,099 +2.9% 0.36% $3,343,079
VANGUARD GROUP INC 3.5% 2,204,294 0% 0% $1,408,544
Skylands Capital, LLC 2.9% 1,854,515 -13% 0.16% $1,185,406
NEUBERGER BERMAN GROUP LLC 2.6% 1,625,640 +1.7% 0% $1,039,597
CM Management, LLC 2.3% 1,476,500 +15% 0.8% $943,779
BlackRock, Inc. 1.2% 770,551 +0.75% 0% $492,536
Sargent Investment Group, LLC 0.97% 612,000 -17% 0.05% $391,190
GEODE CAPITAL MANAGEMENT, LLC 0.96% 603,767 +0.39% 0% $386,034
Pathstone Holdings, LLC 0.79% 499,955 0% $319,571
CIBC Private Wealth Group LLC 0.27% 172,649 0% 0% $110,357
STATE STREET CORP 0.25% 159,293 0% 0% $101,820
CITADEL ADVISORS LLC 0.24% 149,279 +127% 0% $95,419
GSA CAPITAL PARTNERS LLP 0.24% 148,374 +32% 0.01% $95,000
OSAIC HOLDINGS, INC. 0.21% 130,419 0% 0% $83,447
MORGAN STANLEY 0.18% 116,479 +8.6% 0% $74,454
UBS Group AG 0.18% 115,272 +0.06% 0% $73,659
RAYMOND JAMES FINANCIAL INC 0.17% 108,702 -0.02% 0% $69,482
NWF Advisory Services Inc. 0.17% 104,139 0% 0.01% $66,566
RENAISSANCE TECHNOLOGIES LLC 0.16% 100,120 -26% 0% $63,997
NORTHERN TRUST CORP 0.15% 92,540 +1.1% 0% $59,151
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.13% 83,363 -15% 0% $53,286
Key Client Fiduciary Advisors, LLC 0.12% 78,457 0% 0.02% $50,150
Waverly Advisors, LLC 0.09% 55,556 0% 0% $35,511
STIFEL FINANCIAL CORP 0.08% 48,000 0% 0% $30,682
BANK OF AMERICA CORP /DE/ 0.06% 38,706 +0.01% 0% $24,732

Institutional Holders of Cytosorbents Corp - Common Stock (CTSO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,828,701 $1,035,593 -$67,741 $0.57 5
2025 Q4 16,863,149 $10,779,444 +$313,470 $0.64 51
2025 Q3 16,334,989 $15,255,905 -$76,176 $0.93 48
2025 Q2 16,439,150 $20,747,017 -$475,512 $1.28 43
2025 Q1 16,936,549 $16,946,108 +$1,621,898 $1.00 47
2024 Q4 15,331,894 $14,135,595 -$1,258,331 $0.91 49
2024 Q3 16,479,547 $24,719,503 -$163,841 $1.50 52
2024 Q2 16,466,687 $11,576,845 -$649,269 $0.70 44
2024 Q1 17,587,924 $16,695,355 -$483,723 $0.95 48
2023 Q4 18,066,999 $20,043,725 +$3,216,187 $1.11 52
2023 Q3 15,225,693 $28,618,581 -$152,760 $1.88 52
2023 Q2 15,228,799 $54,658,487 +$137,905 $3.59 58
2023 Q1 15,164,229 $51,235,010 +$1,680,617 $3.37 57
2022 Q4 14,633,483 $22,639,263 -$45,975 $1.55 47
2022 Q3 13,738,883 $18,678,835 -$1,556,761 $1.36 51
2022 Q2 15,471,130 $33,885,658 -$6,118,886 $2.19 68
2022 Q1 18,023,750 $57,468,184 +$256,084 $3.19 81
2021 Q4 17,787,059 $74,549,808 -$8,090,953 $4.19 89
2021 Q3 18,365,550 $149,202,914 +$6,984,615 $8.12 93
2021 Q2 17,524,476 $132,378,236 -$233,053 $7.55 97
2021 Q1 17,470,204 $151,609,944 -$1,998,575 $8.68 91
2020 Q4 17,574,310 $140,069,028 +$3,065,684 $7.97 89
2020 Q3 17,195,121 $137,138,701 +$46,357,178 $7.98 94
2020 Q2 11,233,329 $111,252,626 +$14,117,068 $9.90 89
2020 Q1 9,938,360 $76,782,098 +$8,994,470 $7.73 79
2019 Q4 8,941,247 $34,418,814 +$1,513,313 $3.85 70
2019 Q3 8,444,748 $42,473,266 -$1,062,816 $5.03 66
2019 Q2 8,514,726 $56,282,437 +$525,949 $6.61 68
2019 Q1 8,508,451 $64,405,572 -$1,162,319 $7.57 71
2018 Q4 8,656,316 $69,927,146 +$1,133,626 $8.08 82
2018 Q3 8,196,875 $105,728,460 +$5,077,024 $12.90 78
2018 Q2 7,799,450 $88,919,578 +$45,837,712 $11.40 72
2018 Q1 3,924,758 $27,669,000 +$5,315,910 $7.05 47
2017 Q4 3,206,188 $20,847,000 +$4,718,786 $6.50 43
2017 Q3 2,481,878 $15,385,000 +$3,763,184 $6.20 30
2017 Q2 1,938,263 $8,335,000 -$2,210,646 $4.30 30
2017 Q1 2,432,898 $10,945,000 +$4,437,832 $4.50 33
2016 Q4 1,594,528 $8,689,000 +$49,086 $5.45 37
2016 Q3 1,568,958 $10,038,360 -$1,210,437 $6.40 34
2016 Q2 1,773,199 $8,063,000 +$413,105 $4.55 33
2016 Q1 1,405,899 $5,507,447 +$5,695 $3.92 31
2015 Q4 1,375,701 $7,660,000 -$173,999 $5.57 38
2015 Q3 1,350,065 $8,514,000 +$690,433 $6.30 30
2015 Q2 1,241,972 $7,625,037 +$743,226 $6.14 29
2015 Q1 908,197 $11,940,236 +$7,890,541 $13.19 27
2014 Q4 394,240 $3,921,376 +$1,051,376 $9.96 9